Joseph Muenzer
Pediatrics · Chapel Hill, NCNPI 1306926944
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Sanofi at 33.4% of the total. Reporting peaked in 2019 at $102,240 and has fallen 90.8% since, to $9,398 in 2025. Among pediatrics clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $1752.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$79K
- Sanofi-aventis U.S. LLC$63K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- Shire North American Group Inc$41K
- Orchard Therapeutics North America$5K
- Ultragenyx Pharmaceutical Inc.$3K
- plus $36 from 1 others
Across 264 payments — averaging $21,376 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$4.2M
- Shire North American Group Inc$1.1M
- Swedish Orphan Biovitrum AB$266K
- Biomarin Pharmaceutical Inc.$83K
- Sanofi$12K
What the payments were for
- Consulting fees$90,40338%
- Speaking & faculty fees$56,71624%
- Travel & lodging$86,45537%
- Food & beverage$3,0251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 46 | $78,951 |
| Sanofi-aventis U.S. LLC | 16 | $63,262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $46,590 |
| Shire North American Group Inc | 39 | $40,561 |
| Orchard Therapeutics North America | 3 | $4,626 |
| Ultragenyx Pharmaceutical Inc. | 4 | $2,573 |
| Biomarin Pharmaceutical Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALDURAZYME$95,430
- ELAPRASE$44,813
- NO PRODUCT DISCUSSED$19,668
How this compares
$236,599 in reported general payments places this provider in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ElapraseIdursulfase | 13 | $816,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Elaprase | $46,590 | $816,97313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,818 pediatrics providers in North Carolina.
Other pediatrics in Chapel Hill
- Timothy GershonChapel Hill$59K
- Maria EscolarChapel Hill$42K
- David PedenChapel Hill$29K
- Elizabeth JalazoChapel Hill$22K
- Lauren HerlihyChapel Hill$15K
- Steven ZeiselChapel Hill$10K
- Matthew LaughonChapel Hill$10K
- Arvil BurksChapel Hill$8K
- Lindsay TorriceChapel Hill$4K
- Dwight KoeberlDurham$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.